Lilly, Amgen collaborate to boost supply of potential COVID-19 therapies

Lilly, Amgen collaborate to boost supply of potential COVID-19 therapies

Eli Lilly and Company has entered into a global antibody manufacturing collaboration with Amgen to considerably boost the supply capacity for its potential COVID-19 therapies. Currently, Lilly is studying various potential neutralizing antibodies for the prevention and/or treatment of the novel coronavirus as monotherapy or in combination. Through the collaboration, the two US pharma companies […]

SAB Biotherapeutics begins phase 1b Covid-19 trial of SAB-185

SAB Biotherapeutics begins phase 1b Covid-19 trial of SAB-185

SAB Biotherapeutics, a US biopharma company, said that the first patient in a phase 1b clinical trial of its investigational Covid-19 therapeutic SAB-185 has been dosed. The early-stage trial is assessing the safety and pharmacological activity of SAB-185 in Covid-19 patients. SAB-185, which was generated from a subunit of the SARS-CoV-2 Wuhan strain, has delivered […]

BSE Ebix, Universal Sompo partner on Corona Kavach policy and other policies

BSE Ebix, Universal Sompo partner on Corona Kavach policy and other policies

Corona Kavach policy : BSE Ebix Insurance Broking, a joint venture between fintech company Ebix’s subsidiary Ebix Fincorp Exchange and the Bombay Stock Exchange (BSE), has entered into a partnership with Universal Sompo General Insurance to sell general insurance products through the former’s distribution network in a fully digitized environment. Universal Sompo General Insurance is […]

Celltrion begins phase 1 human trial of COVID-19 antiviral antibody candidate

Celltrion begins phase 1 human trial of COVID-19 antiviral antibody candidate

Celltrion Group, a South Korean pharma company, has launched a phase 1 human clinical trial of a potential antiviral antibody treatment for COVID-19 patients. The in-human study of the COVID-19 antiviral antibody comes in the wake of the positive results delivered by it in pre-clinical studies and the following approval of the investigational new drug […]

ChAdOx1 nCoV-19 vaccine : Russia’s R-Pharm signs deal with AstraZeneca

ChAdOx1 nCoV-19 vaccine : Russia’s R-Pharm signs deal with AstraZeneca

Russian pharma company R-Pharm has reportedly signed an agreement with AstraZeneca for manufacturing the ChAdOx1 nCoV-19 vaccine being developed by the latter in collaboration with UK-based Oxford University. The entire world is pinning hopes on the ChAdOx1 nCoV-19 vaccine candidate, which reportedly seems to be the most probable to become the first vaccine against the […]

Celltex Therapeutics gets FDA nod for Covid-19 stem cell clinical trial

Celltex Therapeutics gets FDA nod for Covid-19 stem cell clinical trial

Covid-19 stem cell clinical trial : Celltex Therapeutics has been given the clearance by the US Food and Drug Administration (FDA) to move ahead with a phase 2 clinical trial for investigating the efficacy of autologous adipose tissue-derived mesenchymal stem cells (AdMSCs) in the prevention of Covid-19. In this connection, the Texas-based biotech company had […]

Regeneron Pharmaceuticals begins COVID-19 clinical trials of REGN-COV2

Regeneron Pharmaceuticals begins COVID-19 clinical trials of REGN-COV2

US biotech company Regeneron Pharmaceuticals has started the first clinical trial of its investigational dual antibody cocktail REGN-COV2 (REGN10933+REGN10987) for the prevention and treatment of COVID-19. The REGN-COV2 clinical program will feature four separate study populations, which include hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people in groups that are at high-risk of exposure, […]

Gilead Covid-19 drug candidate remdesivir delivers desired results in phase 3 trial

Gilead Covid-19 drug candidate remdesivir delivers desired results in phase 3 trial

Remdesivir clinical trial results : Gilead Sciences said that the phase 3 SIMPLE trial, which has been evaluating the Covid-19 drug candidate remdesivir for the treatment of hospitalized patients with moderate pneumonia associated with novel coronavirus, has yielded promising results. According to the US biopharma company, the Covid-19 drug candidate delivered significantly greater clinical improvement for […]

Lilly begins phase 1 coronavirus antibody trial with LY-CoV555

Lilly begins phase 1 coronavirus antibody trial with LY-CoV555

Coronavirus antibody trial : US pharma giant Eli Lilly and Company (Lilly) said that patients have been dosed in a phase 1 clinical trial with the investigational antibody LY-CoV555 for the treatment of COVID-19. LY-CoV555 is the first antibody candidate to emerge from Lilly’s collaboration with AbCellera Biologics, which was announced in March 2020, with […]